Freenome is a diagnostics growth story with 106% YoY growth and 53.8% upside to the analyst target, but weak financial quality, negative momentum and a speculative profile with a -42% drawdown make it high risk.
Thesis pillars
- Hypergrowth 106 Percent→Stable
- Weak Financial Quality→Stable
- Large Upside To Target→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Nov 8, 2026, based on the 10-K filed Mar 12, 2026
Freenome, Inc. (FRNM) Stock Analysis
Oversold Bounce setup
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $10.57: Quality below floor (2.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 3.2:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend.
Perceptive Capital Solutions Corp (trading as FRNM) was a blank-check special purpose acquisition company formed in March 2024 to pursue a healthcare or life-sciences business combination, sponsored by an affiliate of Perceptive Advisors. It held $91.9 million in trust as of... Read more
Sell if holding. Engine safety override at $10.57: Quality below floor (2.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 3.2:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: Oversold RSI 19, near Bollinger lower, volume surge. Score 5.6/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
About Freenome, Inc.
About Freenome, Inc.
Perceptive Capital Solutions Corp raised $86.25 million in its June 2024 IPO plus a concurrent private placement, placing $91.9 million in trust as of December 31, 2025 to fund a healthcare-focused business combination. The company is sponsored by an affiliate of Perceptive Advisors, a life-sciences investment firm with more than $9.5 billion in regulatory assets under management and stakes in 234 companies as of December 31, 2025. On December 5, 2025, it signed a Business Combination Agreement with Freenome Holdings, Inc.
As a blank-check company, Perceptive Capital Solutions Corp generated no operating revenue; its only assets were cash and investments held in a trust account established with Continental Stock Transfer & Trust Company as trustee. The company's management team — Chairman Joseph Edelman (founder of Perceptive Advisors), CEO Adam Stone (Perceptive's Chief Investment Officer), and Chief Business Officer Michael Altman — previously sponsored four other ARYA Sciences Acquisition SPACs, which completed mergers with Immatics (now IMTX), Cerevel Therapeutics (acquired by AbbVie in 2024), and Nautilus Biotechnology (now NAUT), while a fifth, ARYA V, liquidated in 2023 without finding a target. The company had 24 months from its IPO closing to complete an initial business combination representing at least 80% of trust-account net assets, structured so the post-combination company would generally acquire 100% of the target's equity, though existing shareholders could retain a minority position depending on deal terms. Affiliates of Perceptive Advisors and board members held 2,156,250 Founder Shares that would lose most of their value if no combination closed in time.
Show full overview
That combination has since closed: an 8-K filed July 24, 2026 discloses that on July 20, 2026, Perceptive Capital Solutions Corp completed its business combination with Freenome Holdings, Inc., first domesticating from a Cayman Islands exempted company into a Delaware corporation before merging Freenome into a wholly-owned subsidiary. The combined entity now trades on Nasdaq under the ticker FRNM as Freenome, Inc., meaning the blank-check structure and trust-account mechanics described in this 10-K no longer reflect the company's current status — the entity has transitioned into an operating company, and its next annual report should describe Freenome's actual liquid-biopsy diagnostics business rather than SPAC search activity.
See also: Healthcare · Diagnostics & Research
From Freenome, Inc.'s most recent 10-K filing, extracted August 9, 2026.
Recent developments
updated Nov 7, 2026Recent Developments — Freenome, Inc.
Latest news
- NEWS Alphabet Discloses Stake in Freenome in Q3 13F Filing — fiscal.ai Nov 7, 2026
- NEWS Freenome Launches SimpleScreen™ Lung Test — fiscal.ai Oct 20, 2026 positive
- NEWS Freenome Unveils SimpleScreen Lung Enabling Patients To Be Screened For Lung And Colorectal Cancer Through Single Blood — benzinga Oct 20, 2026 positive
- NEWS Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up — benzinga Oct 6, 2026 negative
- NEWS Watching Freenome; Traders Circulate Unconfirmed Analyst Comments Suggesting Carelon Healthcare Services (ELV) Just Upda — benzinga Sep 1, 2026 neutral
Latest item Nov 7, 2026 · Generated 2026-11-10T11:47:59Z.
Thesis
Key Metrics
Quality Signals
Material Events(8-K, last 90d)
- 2026-07-24Item 5.01HIGHPerceptive Capital Solutions Corp completed its business combination with Freenome Holdings, Inc. on July 20, 2026, domesticating as a Delaware corporation and merging Freenome into a wholly-owned subsidiary; the combined company continues trading on Nasdaq as Freenome, Inc. under ticker FRNM. Change of control.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $10.57: Quality below floor (2.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 3.2:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: Oversold RSI 19, near Bollinger lower, volume surge. Prior stop was $9.83. Score 5.6/10, moderate confidence.
Analyst target: $15.66 (+48.2% upside). Prior stop was $9.83. Stop-loss: $9.83.
Quality below floor (2.4 < 4.0).
Freenome, Inc. trades at a P/E of N/A (forward -4.4). TrendMatrix value score: 5.4/10. Verdict: Sell.
11 analysts rate FRNM, with a consensus score of 4.5/5. 5 analysts publish price targets averaging $18.
What does Freenome, Inc. do?Perceptive Capital Solutions Corp (trading as FRNM) was a blank-check special purpose acquisition company formed in...
Perceptive Capital Solutions Corp (trading as FRNM) was a blank-check special purpose acquisition company formed in March 2024 to pursue a healthcare or life-sciences business combination, sponsored by an affiliate of Perceptive Advisors. It held $91.9 million in trust as of December 31, 2025 and, per a July 2026 8-K, completed its business combination with Freenome Holdings, Inc. on July 20, 2026, with the combined company continuing to trade under the FRNM ticker as Freenome, Inc.